Merck Secures First Oral PCSK9 Inhibitor, Boosts Q1 2026 Earnings and Expands Oncology Pipeline

Merck’s latest triumph—an FDA nod for its first oral PCSK9 inhibitor—comes on the heels of a stronger‑than‑exp...

Read story →

Indivior Prepares for Q1 2026 Earnings Amid Legal Scrutiny and Product Pipeline Developments

Indivior Pharmaceuticals Inc. (NASDAQ: INDV) will report its first‑quarter 2026 financial results on Thursday, April 3...

Read story →